Menu
Search
|

Menu

Close
X

DelMar Pharmaceuticals Inc DMPI.OQ (NASDAQ Stock Exchange Capital Market)

0.65 USD
+0.04 (+6.12%)
As of 1:30 AM IST
chart
Previous Close 0.61
Open 0.62
Volume 8,449
3m Avg Volume 33,886
Today’s High 0.65
Today’s Low 0.62
52 Week High 2.83
52 Week Low 0.61
Shares Outstanding (mil) 21.55
Market Capitalization (mil) 19.05
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
2.00 Mean rating from 2 analysts

KEY STATS

Revenue (mm, USD)
FY18
0
FY17
0
FY16
0
FY15
0
EPS (USD)
FY18
-0.450
FY17
-0.735
FY16
-0.829
FY15
-0.477
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
19.70
Price to Sales (TTM)
vs sector
--
5.84
Price to Book (MRQ)
vs sector
--
2.75
Price to Cash Flow (TTM)
vs sector
--
24.44
Total Debt to Equity (MRQ)
vs sector
0.00
71.27
LT Debt to Equity (MRQ)
vs sector
0.00
31.54
Return on Investment (TTM)
vs sector
-992.44
0.48
Return on Equity (TTM)
vs sector
--
15.45

EXECUTIVE LEADERSHIP

Robert Hoffman
Chairman of the Board, Since 2018
Salary: --
Bonus: --
Saiid Zarrabian
President, Chief Executive Officer, Director, Since 2018
Salary: --
Bonus: --
Scott Praill
Chief Financial Officer, Since 2013
Salary: $240,000.00
Bonus: $40,000.00
Dennis Brown
Chief Scientific Officer, Director, Since 2013
Salary: $175,000.00
Bonus: $40,000.00
John Bell
Lead Independent Director, Since 2013
Salary: --
Bonus: --

COMPANY PROFILE

Sector: Financials
Industry: Holding Companies
Address:

999 Broadway W Suite 720
VANCOUVER   BC   V5Z 1K5

Phone: +1604.6295989

DelMar Pharmaceuticals, Inc. is a clinical-stage drug development company. The Company focuses on the treatment of cancer. The Company is engaged in conducting clinical trials in the United States with its product candidate, VAL-083, as a treatment for glioblastoma multiforme (GBM), a form of brain cancer. VAL-083 is being evaluated in a Phase II clinical trial for the treatment of refractory GBM. In addition to its clinical development activities in the United States, the Company has obtained certain commercial rights to VAL-083 in China where it is approved as a chemotherapy for the treatment of chronic myelogenous leukemia (CML) and lung cancer. Its drug discovery research focuses on identifying validated clinical and commercial-stage compounds, and establishing a scientific rationale for development in orphan drug indications. VAL-083 is an alkylating agent, which crosses the blood-brain-barrier (BBB).

SPONSORED STORIES